Journal Article

Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin

Saha, Chandan K., Engel, Samuel S., Zeitler, Philip, Lam, Raymond L. H., Zhang, Yilong, Shehadeh, Naim, Golm, Gregory T., Shankar, R. Ravi, Samoilova, Yulia, Kaufman, Keith D., Deeb, Asma, Newfield, Ron S., Jalaludin, Muhammad Yazid, Zilli, Martina, Garcia, Raymundo, Scherer, Lynn W., Rosario, Carmen A.

2022

Overview

Objective To assess the efficacy and safety of sitagliptin in youth with type 2 diabetes (T2D) inadequately controlled with metformin ± insulin. Study Design Data were pooled from two 54‐week, double‐blind, randomized, placebo‐controlled studies of sitagliptin 100 mg daily or placebo added onto treatment of 10‐ to 17‐year‐old youth with T2D and inadequate glycemic control on metformin ± insulin. Participants (N = 220 randomized and treated) had HbA1c 6.5%–10% (7.0%–10% if on insulin), were overweight/obese at screening or diagnosis and negative for pancreatic autoantibodies. The primary endpoint was change from baseline in HbA1c at Week 20. Results Treatment groups were well balanced at baseline (mean HbA1c = 8.0%, BMI = 30.9 kg/m2, age = 14.4 years [44.5% <15], 65.9% female). The dose of background metformin was >1500 mg/day for 71.8% of participants; 15.0% of participants were on insulin therapy. At Week 20, LS mean changes from baseline (95% CI) in HbA1c for sitagliptin/metformin and placebo/metformin were −0.58% (−0.94, −0.22) and −0.09% (−0.43, 0.26), respectively; difference = −0.49% (−0.90, −0.09), p = 0.018; at Week 54 the LS mean (95% CI) changes were 0.35% (−0.48, 1.19) and 0.73% (−0.08, 1.54), respectively. No meaningful differences between the adverse event profiles of the treatment groups emerged through Week 54. Conclusions These results do not suggest that addition of sitagliptin to metformin provides durable improvement in glycemic control in youth with T2D. In this study, sitagliptin was generally well tolerated with a safety profile similar to that reported in adults. (ClinicalTrials.gov: NCT01472367, NCT01760447; EudraCT: 2011‐002529‐23/2014‐003583‐20, 2012‐004035‐23).

• Publisher: John Wiley & Sons A/S,John Wiley & Sons, Inc
• Subject: Administration, Oral / Adolescent / Antidiabetics / antihyperglycemic agents / Autoantibodies / Blood Glucose - analysis / Body weight / Child / Diabetes / Diabetes mellitus (non-insulin dependent) / Diabetes Mellitus, Type 2 - drug therapy / Diabetes Mellitus, Type 2 - physiopathology / dipeptidyl peptidase‐4 inhibitor / Double-Blind Method / DPP‐4 / Drug Therapy, Combination - methods / Drug Therapy, Combination - statistics & numerical data / Female / Glycated Hemoglobin A - analysis / Humans / Hypoglycemic Agents - pharmacology / Hypoglycemic Agents - therapeutic use / incretin / Insulin / Male / Metformin / Metformin - pharmacology / Metformin - therapeutic use / MK‐0431 / Overweight / Patient Safety - standards / Patient Safety - statistics & numerical data / pediatric / Placebos / Safety / Sitagliptin Phosphate - pharmacology / Sitagliptin Phosphate - therapeutic use / Treatment Outcome / youth‐onset type 2 diabetes